Study of Combination of Sorafenib With Cisplatin and 5-fluorouracil as First-line Treatment of Recurrence After Radiotherapy Patients Who Failed With Radiotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)

NCT00747799 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

54

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Neoplasms

Interventions

DRUG: Sorafenib plus Cisplatin and 5-fluorouracil

Sponsor

Sun Yat-sen University